July 31, 2019 / Clinical Trials

PTC Therapeutics Update on Specialty Pharmacy Transition

PTC Therapeutics has shared an update regarding the transitioning of patients that are taking EMFLAZA® (deflazacort) to a new specialty pharmacy, Accredo.

Read the Update from PTC:

PTC Therapeutics Update on Specialty Pharmacy Transition

In June we began transitioning patients that are taking EMFLAZA® (deflazacort) to a new specialty pharmacy, Accredo. We made the move because we feel Accredo is best suited to support the needs of our patients, caregivers and health care providers long term. Accredo has a long history with the rare disorder community, and we believe they have the expertise to meet the needs of PTC patients and families as our company grows.

During the initial phase of the specialty pharmacy transition, we’ve learned of some issues, and we want you to know that we are aware of these and we are working hard to ensure they are resolved.

Meeting your needs and ensuring access to EMFLAZA is our number one goal. Accredo will be contacting patients who show in their record that they have less than 7 days of supply remaining to make arrangements for a refill. If you have 7 days or less supply on-hand of EMFLAZA and have not heard from the pharmacy, or if you are experiencing any issues, inconveniences, or simply have a question please contact PTC Cares at 1-844 4PTCCARES (844-478-2227) to speak to a case manager.

We have expanded our dedicated team of PTC Cares Specialists who can help with transferring your records, processing shipments, assisting with insurance coverage and reimbursement, or any other matter. The PTC Cares team is available from 8 a.m. – 8 p.m. ET Monday-Friday and will return any messages within 24 hours. Messages left after hours will be answered the next business day.

We sincerely apologize for any issue or inconvenience this transition has caused. We know how important access to our therapies is for our patients and caregivers, which is why we are continually looking for ways to better serve you. We will continue to work tirelessly to resolve any issues.

Click here to read more.

Join Our Mailing List